| SEGMENT REPORTING |
22. SEGMENT REPORTING
The Company’s chief operating decision maker
evaluates segment performance and allocates resources based on several factors, of which the primary financial measure is operating income.
The Company acquired the 3D Global Patent and
EG BioMed Patent in June 2024 and commenced the pancreatic cancer early detection service and sales of contact lens business. For
the year ended December 31, 2025, revenue of $35,000 was generated from 3D Global Patent and there was no revenue generated from the patents
for the year ended December 31, 2024.
The Company primarily operates in the ROC and
substantially all of the Company’s long-lived assets are located in the ROC. The Company provides Laboratory Developed Test (LDT)
services to healthcare professionals across the United States.
YD Bio’s chief operating decision maker
evaluates performance based on a single reporting segment’s net revenues, cost of revenues, operating expenses, operating income
(loss), finance income (expense), other income and net income. Net revenue, cost of revenues, operating expenses, operating loss,
finance income, other income (expenses) and net loss by diverse operations for the year ended December 31, 2025, and 2024 were as follows:
| For year ended December
31, 2025 | |
Sales
of medical
and other
related products | | |
Research and
development of
pancreatic
cancer early
detection
services | | |
Research and
development of
sales of contact
lenses | | |
Corporate
unallocated | | |
Consolidated | |
| Net revenues | |
$ | 561,817 | | |
$ | — | | |
$ | 35,000 | | |
$ | — | | |
$ | 596,817 | |
| Cost of revenues | |
| (401,264 | ) | |
| — | | |
| (28,143 | ) | |
| — | | |
| (429,407 | ) |
| Gross profit | |
| 160,553 | | |
| — | | |
| 6,857 | | |
| — | | |
| 167,410 | |
| Total operating expenses | |
| (444,208 | ) | |
| (143,927 | ) | |
| (1,805,720 | ) | |
| (3,045,276 | ) | |
| (5,439,131 | ) |
| Operating loss | |
| (283,655 | ) | |
| (143,927 | ) | |
| (1,798,863 | ) | |
| (3,045,276 | ) | |
| (5,271,721 | ) |
| Finance income, net | |
| 18,397 | | |
| — | | |
| — | | |
| 61,765 | | |
| 80,162 | |
| Other income (expenses), net | |
| 46,942 | | |
| — | | |
| — | | |
| (139 | ) | |
| 46,803 | |
| Change in fair value of warrant liabilities | |
| — | | |
| — | | |
| — | | |
| (3,168,091 | ) | |
| (3,168,091 | ) |
| Income tax expenses | |
| 1,531 | | |
| — | | |
| — | | |
| — | | |
| 1,531 | |
| Net loss | |
| (216,785 | ) | |
| (143,927 | ) | |
| (1,798,863 | ) | |
| (6,151,741 | ) | |
| (8,311,316 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| As of December 31, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | |
| Identifiable long-lived assets | |
| 67,810 | | |
| 1,722,600 | | |
| 887,139 | | |
| — | | |
| 2,677,549 | |
| Total assets | |
$ | 2,337,152 | | |
$ | 1,722,600 | | |
$ | 887,139 | | |
$ | 8,832,506 | | |
$ | 13,779,397 | |
| For year ended December 31, 2024 | |
Sales of
medical
and other
related products | | |
Research and
development of
pancreatic
cancer early
detection
services | | |
Research and
development of
sales of contact
lenses | | |
Corporate
unallocated | | |
Consolidated | |
| Net revenues | |
$ | 510,360 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 510,360 | |
| Cost of revenues | |
| (355,004 | ) | |
| — | | |
| — | | |
| — | | |
| (355,004 | ) |
| Gross profit | |
| 155,356 | | |
| — | | |
| — | | |
| — | | |
| 155,356 | |
| Total operating expenses | |
| (447,642 | ) | |
| (53,678 | ) | |
| (469,158 | ) | |
| (646,808 | ) | |
| (1,617,286 | ) |
| Operating loss | |
| (292,286 | ) | |
| (53,678 | ) | |
| (469,158 | ) | |
| (646,808 | ) | |
| (1,461,930 | ) |
| Finance income, net | |
| 10,068 | | |
| — | | |
| — | | |
| 968 | | |
| 11,036 | |
| Other income (expenses), net | |
| 64,444 | | |
| — | | |
| — | | |
| (29 | ) | |
| 64,415 | |
| Income tax expenses | |
| (25,080 | ) | |
| — | | |
| — | | |
| — | | |
| (25,080 | ) |
| Net loss | |
| (242,854 | ) | |
| (53,678 | ) | |
| (469,158 | ) | |
| (645,869 | ) | |
| (1,411,559 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| As of December 31, 2024 | |
| | | |
| | | |
| | | |
| | | |
| | |
| Identifiable long-lived assets | |
| 88,077 | | |
| 1,769,000 | | |
| 911,035 | | |
| — | | |
| 2,768,112 | |
| Total assets | |
$ | 2,219,996 | | |
$ | 1,769,000 | | |
$ | 911,035 | | |
$ | 1,964,195 | | |
$ | 6,864,226 | |
|